Latest Intelligence in France

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

New personal care review: toothbrushes get a handle on replacement indicator technology

This month's rundown of the latest personal care launches looks at how toothbrush indicator technology is taking strides forward, with a recent innovative launch featuring an integrated device in the handle showing when the toothbrush should be replaced. In other news, the trend for personal care products to mimic indulgent food continues with the launch of a bath soap "chocolate bar."

Published By Datamonitor
18 Jul 2012
Expert View
Expert View

GDF and the French government fight over gas prices

French utility GDF Suez has gained the upper hand in its battle with the French government over the sensitive issue of gas prices. GDF Suez has succeeded in overturning a gas price freeze announced by the French government in Q4 2011. As a result, consumers will need to pay the price difference for the quarter, and gas prices will continue to be a politically sensitive topic.

Published By Datamonitor
18 Jul 2012
Expert View
Expert View

New drinks review: canned drinks go healthy with vegetable innovations

Unusual vegetable-based drinks are the highlight of this month's roundup of innovative product launches from the drinks industry, as canned tomato and zucchini drinks hit the shelves. In other news, drinking chocolate is a focus of innovation, with two novel formulations, while concerns about pack security and hygiene have extended to energy drinks with the launch of a new lidded can design.

Published By Datamonitor
14 Jun 2012
Expert View
Expert View

New food review: glitter and gold add sparkle to gum and jam

Glitter effects are being increasingly used by manufacturers, as seen in this month's round-up of novel food introductions, with recent innovations including gum coated in "beaten silver" and jam featuring edible gold. Soup, meanwhile, has borrowed an idea from hot drinks with the launch of a self-heating pouch, while economy branding has taken an irreverent turn with the launch of "crisis chips."

Published By Datamonitor
14 Jun 2012
Expert View
Expert View

Johnson & Johnson: can canagliflozin do what dapa didn't?

New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.

Published By Datamonitor
14 Jun 2012
Expert View
Expert View

India climbs into the top 10 wealth markets list

The global wealth market declined in 2011 after two years of robust recovery, with the eurozone sovereign crisis, natural calamities, and stock market volatility taking their toll. Uncertainty about the future of the euro and the worsening of the sovereign crisis in Europe are predicted to cause continuing problems, but many emerging markets are expected to continue marching ahead.

Published By Datamonitor
29 May 2012
Expert View
Expert View

APA 2012: standout schizophrenia and bipolar depression data for Latuda steal the show

New clinical data were presented at APA 2012 that showed that Latuda is effective as an adjunctive treatment for bipolar depression and may possess a procognitive effect in schizophrenia patients. These findings set Latuda apart from the competition and may allow the drug to shine in a fiercely competitive antipsychotics market.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: diagnostic overhaul will shape psychiatry drug markets

The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: cariprazine fails to offer a therapeutic breakthrough

Forest and Gedeon's cariprazine is a pharmacologically unique atypical antipsychotic in Phase III development for both schizophrenia and bipolar mania. Data presented at APA 2012 hint that while cariprazine appears to be effective in both indications, its tolerability and failure to address the broader bipolar depression patient population will hinder uptake.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: Forest's latest antidepressants will have diverging fortunes

Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.

Published By Datamonitor
15 May 2012

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.